Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He is currently finishing up a Master’s degree in communications at Georgetown University.

Latest Posts

Forbes Asks: Should Economists Perform Surgery and Doctors Conduct Economic Policy?

TheHill

Over at Forbes, University of Chicago economist Tomas Philipson has an insightful post analyzing several of the arguments frequently made in recent debates about the price and value of innovative medicines. Philipson argues that physicians are often self-interested as buyers when complaining about drug prices, and often fail to understand the broader economic context in which drug pricing decisions must be made: “Just as you wouldn’t let a financial planner perform cancer surgery, we shouldn’t Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Measles Outbreak Shows Dangers of Vaccine Misinformation

Vaccination

On Sunday, Centers for Disease Control (CDC) Director Tom Friedan said that the U.S. could be faced with a “large outbreak” of measles, according to the Washington Post. The agency reported that 102 cases of measles were confirmed in 14 states in January. Hundreds of others are being monitored for possible exposure. The majority of the confirmed cases are among patients who have not been vaccinated, illustrating the danger posed to both individual and public Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Hill: Will Support for Biomedical Research Be Dead on Arrival?

ebola

In an op-ed over at The Hill, Dr. Claire Pomeroy, an infectious disease specialist and president of the Albert and Mary Lasker Foundation, discusses an important question: “How is it that the United States, which has historically held the global lead in medical innovation, was caught flat-footed by Ebola?” Dr. Pomeroy points to a lack of federal funding for medical research as one of the primary culprits for our lack of effective Ebola answers, a Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Bavarian Nordic CEO Paul Chaplin in San Jose Mercury News: Why an Ebola Vaccine Still Matters

ebola

The San Jose Mercury News this weekend published an op-ed by Paul Chaplin, the CEO of Bavarian Nordic and a co-chair of the Alliance for Biosecurity which discussed the continuing need to develop an Ebola vaccine – as well as continued federal investments in the programs which fund such research. As Dr. Chaplin notes, all of the Ebola drug and vaccine candidates currently in development have received U.S. federal funding. Why do medical countermeasures against Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

PBS Newshour: What you need to know about this year’s elevated flu threat

flu-vaccines

PBS Newshour last week had a segment about this year’s flu season, which doctors are warning could be more severe than normal. One reason for that is that one of the flu virus strains that is most prevalent is not responding as well as usual to the vaccine. LJ Tan explains: …with this upcoming season, we are getting a predominance of H3N2. That means we might have a more severe season. But not only that Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,